Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis

被引:64
作者
Dhaun, Neeraj [1 ]
Lilitkarntakul, Pajaree [1 ]
MacIntyre, Iain M. [1 ]
Muilwijk, Eline [1 ]
Johnston, Neil R. [1 ]
Kluth, David C. [2 ]
Webb, David J. [1 ]
Goddard, Jane [3 ]
机构
[1] Univ Edinburgh, Queens Med Res Inst, Clin Pharmacol Unit, Edinburgh EH16 4TJ, Midlothian, Scotland
[2] Univ Edinburgh, Queens Med Res Inst, Ctr Inflammat Res, Edinburgh EH16 4TJ, Midlothian, Scotland
[3] Royal Infirm Edinburgh NHS Trust, Dept Renal Med, Edinburgh, Midlothian, Scotland
关键词
systemic lupus erythematosus; renal inflammation; biomarker; REACTIVE PROTEIN MEASUREMENT; PLASMA ENDOTHELIN; RENAL ENDOTHELIN; RECEPTOR; ERYTHEMATOSUS; EXCRETION; INFLAMMATION; DYSFUNCTION; ANTAGONISM; EXPRESSION;
D O I
10.1152/ajprenal.90713.2008
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Dhaun N, Lilitkarntakul P, MacIntyre IM, Muilwijk E, Johnston NR, Kluth DC, Webb DJ, Goddard J. Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol 296: F1477-F1483, 2009. First published March 11, 2009; doi:10.1152/ajprenal.90713.2008.-Chronic inflammation contributes to the development and progression of chronic kidney disease (CKD). Identifying renal inflammation early is important. There are currently no specific markers of renal inflammation. Endothelin-1 (ET-1) is implicated in the pathogenesis of CKD. Thus, we investigated the impact of progressive renal dysfunction and renal inflammation on plasma and urinary ET-1 concentrations. In a prospective study, plasma and urinary ET-1 were measured in 132 subjects with CKD stages 1 to 5, and fractional excretion of ET-1 (FeET-1) was calculated. FeET-1, serum C-reactive protein (CRP), urinary ET-1: creatinine ratio, and urinary albumin: creatinine ratio were also measured in 29 healthy volunteers, 85 subjects with different degrees of inflammatory renal disease but normal renal function, and in 10 subjects with rheumatoid arthritis without renal involvement (RA). In subjects with nephritis associated with systemic lupus erythematosus (SLE), measurements were done before and after 6 mo of treatment. In subjects with CKD, plasma ET-1 increased linearly as renal function declined, whereas FeET-1 rose exponentially. In subjects with normal renal function, FeET-1 and urinary ET-1: creatinine ratio were higher in SLE subjects than in other groups (7.7 +/- 2.7%, 10.0 +/- 3.0 pg/mu mol, both P < 0.001), and correlated with CRP, and significantly higher than in RA subjects (both P < 0.01) with similar CRP concentrations. In SLE patients, following treatment, FeET-1 fell to 3.6 +/- 1.4% (P < 0.01). Renal ET-1 production increases as renal function declines. In subjects with SLE, urinary ET-1 may be a useful measure of renal inflammatory disease activity while measured renal function is still normal.
引用
收藏
页码:F1477 / F1483
页数:7
相关论文
共 41 条
[1]   VALUE OF SERUM C-REACTIVE PROTEIN MEASUREMENT IN THE INVESTIGATION OF FEVER IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
BECKER, GJ ;
WALDBURGER, M ;
HUGHES, GRV ;
PEPYS, MB .
ANNALS OF THE RHEUMATIC DISEASES, 1980, 39 (01) :50-52
[2]   Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria [J].
Benigni, A ;
Corna, D ;
Zoja, C ;
Longaretti, L ;
Gagliardini, E ;
Perico, N ;
Coffman, TM ;
Remuzzi, G .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (10) :2666-+
[3]   A SPECIFIC ENDOTHELIN SUBTYPE-A RECEPTOR ANTAGONIST PROTECTS AGAINST INJURY IN RENAL-DISEASE PROGRESSION [J].
BENIGNI, A ;
ZOJA, C ;
CORNA, D ;
ORISIO, S ;
LONGARETTI, L ;
BERTANI, T ;
REMUZZI, G .
KIDNEY INTERNATIONAL, 1993, 44 (02) :440-444
[4]   INCREASED RENAL ENDOTHELIN PRODUCTION IN RATS WITH REDUCED RENAL MASS [J].
BENIGNI, A ;
PERICO, N ;
GASPARI, F ;
ZOJA, C ;
BELLIZZI, L ;
GABANELLI, M ;
REMUZZI, G .
AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 260 (03) :F331-F339
[5]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[6]   PLASMA ENDOTHELIN CORRELATES WITH THE EXTENT OF PULMONARY-HYPERTENSION IN PATIENTS WITH CHRONIC CONGESTIVE-HEART-FAILURE [J].
CODY, RJ ;
HAAS, GJ ;
BINKLEY, PF ;
CAPERS, Q ;
KELLEY, R .
CIRCULATION, 1992, 85 (02) :504-509
[7]   Endothelin-1 levels and conduit artery mechanical properties in end-stage renal disease [J].
Dammers, R ;
Hoeks, APG ;
Tordoir, JHM ;
Welten, RJTJ ;
Hamulyák, K ;
Kooman, JP ;
Kitslaar, PJEHM .
BLOOD PURIFICATION, 2005, 23 (03) :190-195
[8]   Endothelin and cardiovascular remodelling in end-stage renal disease [J].
Demuth, K ;
Blacher, J ;
Guerin, AP ;
Benoit, MO ;
Moatti, N ;
Safar, ME ;
London, GM .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (02) :375-383
[9]   The endothelin system and its antagonism in chronic kidney disease [J].
Dhaun, Neeraj ;
Goddard, Jane ;
Webb, David J. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (04) :943-955
[10]  
DUBOIS D, 1989, NUTRITION, V5, P303